Login to Your Account

Vernalis Raising £30M to Buy Back EU Rights to Frovatriptan

By Nuala Moran

Wednesday, February 17, 2010
LONDON - Vernalis plc is raising £30 million (US$47.1 million) in a placing to buy back the European rights to frovatriptan, the drug which took the company to the brink when it failed to get FDA approval in treating menstrual migraine in 2007. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription